N-Glycosylation is a key modification process of many important proteins, affecting the stability and activity of proteins, thereby participating in the regulation of biological processes such as cell signaling, immune response, and virus invasion. Develop appropriate N-glycosylation inhibitors as research tools to help deeply understand and elucidate the mechanism of N-glycosylation's impact on cell functions and disease development, and provide important means for research in related fields. As one of the world's most influential biological companies, CD BioGlyco provides various types of N-glycosylation inhibitor development services, including polyol precursor assembly inhibitors, N-glycosylation processing enzyme inhibitors, substrate analog-based N-glycosylation inhibitors and blocking N-glycan-protein interaction inhibitors. Professional N-glycosylation inhibitor development services mainly include the following contents.
CD BioGlyco first identifies the protein or enzyme of interest as a target for the development of N-glycosylation inhibitors. High-throughput screening technology and computational simulation methods are then used to screen candidate compounds with potential N-glycosylation inhibitory activity from the compound library. Based on the structure and active site information of the target protein, N-glycosylation inhibitors with appropriate molecular structures are designed. Subsequently, the activity, selectivity, and sample stability of inhibitors are improved through reasonable chemical modification, molecular simulation, and structure-activity relationship studies.
CD BioGlyco provides synthesis and purification for screened N-glycosylation inhibitors. Based on the structure and characteristics of the inhibitors obtained through screening, we determine synthetic pathways and methods, use appropriate reagents, solvents, and conditions for the reaction, and perform necessary purification and crystallization steps to obtain the required N-glycosylation inhibitors. At the same time, we conduct comprehensive analysis and characterization of the synthesized N-glycosylation inhibitors to ensure that their structure and purity meet the requirements. Commonly used analytical techniques include nuclear magnetic resonance (NMR) spectroscopy, mass spectrometry (MS), infrared spectroscopy (IR), high-performance liquid chromatography (HPLC), etc.
CD BioGlyco evaluates the activity of optimized N-glycosylation inhibitors and uses in vitro experimental methods to evaluate the inhibitory effect on target proteins or enzymes. For example, determine the inhibition constant, the IC50 value of the inhibitor, and the effect on N-glycosylation modification in a specific cell line.
CD BioGlyco also provides pharmacokinetic (absorption, distribution, metabolism, and excretion/elimination (ADME)) and toxicological evaluation for developed N-glycosylation inhibitors to assess the safety of the candidate inhibitors.
In addition, we also provide large-scale production for N-glycosylation inhibitors after inhibitors pass preliminary experimental verification, we will optimize the synthesis process route and control the production quality of inhibitors to ensure the production of N-glycosylation inhibitors that meet specifications.
Fig.1 N-Glycosylation inhibitor development services. (CD BioGlyco)
CD BioGlyco targets the polyol precursor assembly process in N-glycosylation and develops suitable inhibitors to interfere with or slow down the progress of this process, thereby intervening in the pathological processes of related diseases and providing new solutions for disease research.
The maturation of newly generated N-linked chains transferred to glycoprotein substrates requires the action of processing enzymes such as α-glucosidase and α-mannosidase. CD BioGlyco provides mature N-glycosylation processing enzyme inhibitor development service.
CD BioGlyco provides specialized substrate analog-based N-glycosylation inhibitor development service. Our research focuses on the direction of acceptor analogs, donor analogs, and dual substrate inhibitors of N-glycosylation-related enzymes.
CD BioGlyco uses a structure-based drug design approach to obtain inhibitors that block N-glycan-protein interactions. We provide screening or synthesis for inhibitors that block N-glycan-protein interactions without affecting other protein interactions.
Technology: Cell extraction or chemical synthesis
Journal: Critical Reviews in Biochemistry and Molecular Biology
Results: The authors described a variety of inhibitors of N-linked glycans, most of which target early steps in the biosynthetic pathway and affect the assembly of all types of N-linked chains. Tunicamycin was a nucleoside analog isolated from Streptomyces streptolyticum and was a polyol precursor assembly inhibitor. Castanospermine inhibited α-glucosidase I and II, and deoxymannojirimycin inhibited ER α-mannosidase I, they were widely used processing enzyme inhibitors. N-Glycosylation inhibitors were very useful for studying the biological functions of N-glycans in cells or tissues.
Fig.2 Various N-glycosylation inhibitors. (Brown, et al., 2007)
CD BioGlyco has an experienced team of scientists and technicians who efficiently execute N-glycosylation inhibitor development projects and solve problems that may arise. We are committed to delivering high-quality N-glycosylation inhibitor development results and ensuring that our clients' expectations are met or exceeded. Please feel free to contact us if you are interested in our inhibitor development services.